Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04785534 · ClinicalTrials.gov registry record · NA
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
A NA study of Liver and Intrahepatic Bile Duct Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT04785534 is a NA study of Liver and Intrahepatic Bile Duct Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,000 participants, above the 32-participant average among 3 other Liver and Intrahepatic Bile Duct Carcinoma trials with a reported enrollment target (3025% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04785534, a NA study of Liver and Intrahepatic Bile Duct Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Survey Administration
- OTHER Clinical Evaluation
- PROCEDURE Liver Ultrasonographic Elastography
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04785534
The ClinicalTrials.gov registry entry for NCT04785534 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 32-participant average among 3 other Liver and Intrahepatic Bile Duct Carcinoma trials with a reported enrollment target (3025% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver and Intrahepatic Bile Duct Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT04785534 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04785534 about?
NCT04785534 is a clinical study titled "Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis". This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Informati...
What is the current status of trial NCT04785534?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2020-12-22. Estimated completion is 2026-08-31.
What conditions does trial NCT04785534 study?
This clinical trial studies the following conditions: Liver and Intrahepatic Bile Duct Carcinoma.
What interventions are being tested in trial NCT04785534?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Survey Administration (OTHER), Clinical Evaluation (OTHER), Liver Ultrasonographic Elastography (PROCEDURE).
Who is sponsoring clinical trial NCT04785534?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04785534 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver and Intrahepatic Bile Duct Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
RECRUITING · NA
-
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.